Treatment with CD9 enriched EV was able to increase the cellular proliferation of androgen-deprived LNCaP cells independently of DHT, thereby demonstrating a role of CD9 through EV in prostate cancer cell proliferation. This evidence concerns the gene CD9 and prostate cancer.